Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Phenoptin (sapropterin) in PKU Subjects from PKU-004 or PKU-006
2006-000839-10Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- May 2006
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sapropterin in phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Long-term safety of Phenoptin (sapropterin). Started May 2006; status: completed.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2006-000839-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000839-10.